

FORM D
Notice of Exempt Offering of Securities

UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.

OMB APPROVAL
OMB Number: 3235-0076
Expires: August 31, 2015
Estimated Average burden hours per response: 4.0

1. Issuer's Identity

CIK (Filer ID Number)	Previous Name(s) <input checked="" type="checkbox"/> None	Entity Type
<input type="text" value="0001444192"/>		<input checked="" type="radio"/> Corporation
Name of Issuer		<input type="radio"/> Limited Partnership
<input type="text" value="Acasti Pharma Inc."/>		<input type="radio"/> Limited Liability Company
Jurisdiction of Incorporation/Organization		<input type="radio"/> General Partnership
<input type="text" value="QUEBEC, CANADA"/>		<input type="radio"/> Business Trust
Year of Incorporation/Organization		<input type="radio"/> Other
<input checked="" type="radio"/> Over Five Years Ago		
<input type="radio"/> Within Last Five Years (Specify Year)	<input type="text"/>	
<input type="radio"/> Yet to Be Formed		

2. Principal Place of Business and Contact Information

Name of Issuer			
<input type="text" value="Acasti Pharma Inc."/>			
Street Address 1		Street Address 2	
<input type="text" value="545 Promende du Centropolis"/>		<input type="text" value="Suite 100"/>	
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer
<input type="text" value="Laval"/>	<input type="text" value="QUEBEC, CANADA"/>	<input type="text" value="H7T 0A3"/>	<input type="text" value="(450) 686-4555"/>

3. Related Persons

Last Name	First Name	Middle Name
<input type="text" value="D'Alvise"/>	<input type="text" value="Janelle"/>	
Street Address 1		Street Address 2
<input type="text" value="545 Promenade du Centropolis"/>		<input type="text" value="Suite 100"/>
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Laval"/>	<input type="text" value="QUEBEC, CANADA"/>	<input type="text" value="H7T 0A3"/>
Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director
		<input type="checkbox"/> Promoter
Clarification of Response (if Necessary)		

Last Name	First Name	Middle Name
<input type="text" value="O'Keefe"/>	<input type="text" value="Linda"/>	<input type="text" value="P."/>
Street Address 1		Street Address 2
<input type="text" value="545 Promenade du Centropolis"/>		<input type="text" value="Suite 100"/>
City	State/Province/Country	ZIP/Postal Code
<input type="text" value="Laval"/>	<input type="text" value="QUEBEC, CANADA"/>	<input type="text" value="H7T 0A3"/>

Relationship:	<input checked="" type="checkbox"/> Executive Officer	<input type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	---	-----------------------------------	-----------------------------------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Carter	Roderick	N.

Street Address 1	Street Address 2	
545 Promenade du Centropolis	Suite 100	
City	State/Province/Country	ZIP/Postal Code
Laval	QUEBEC, CANADA	H7T 0A3

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Canan	Jean-Marie (John)	

Street Address 1	Street Address 2	
545 Promenade du Centropolis	Suite 100	
City	State/Province/Country	ZIP/Postal Code
Laval	QUEBEC, CANADA	H7T 0A3

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Olds	Donald	

Street Address 1	Street Address 2	
545 Promenade du Centropolis	Suite 100	
City	State/Province/Country	ZIP/Postal Code
Laval	QUEBEC, CANADA	H7T 0A3

Relationship:	<input type="checkbox"/> Executive Officer	<input checked="" type="checkbox"/> Director	<input type="checkbox"/> Promoter
---------------	--	--	-----------------------------------

Clarification of Response (if Necessary)

4. Industry Group

- ☐ Agriculture
- ☐ Banking & Financial Services
- ☐ Commercial Banking
- ☒ Health Care
- ☐ Biotechnology
- ☐ Health Insurance
- ☐ Hospitals & Physicians
- ☐ Retailing
- ☐ Restaurants
- ☐ Technology

<input type="radio"/> Insurance	<input type="radio"/> Pharmaceuticals	<input type="radio"/> Computers
<input type="radio"/> Investing	<input type="radio"/> Other Health Care	<input type="radio"/> Telecommunications
<input type="radio"/> Investment Banking		<input type="radio"/> Other Technology
<input type="radio"/> Pooled Investment Fund		
<input type="radio"/> Other Banking & Financial Services	<input type="radio"/> Manufacturing	Travel
<input type="radio"/> Business Services	Real Estate	<input type="radio"/> Airlines & Airports
Energy	<input type="radio"/> Commercial	<input type="radio"/> Lodging & Conventions
<input type="radio"/> Coal Mining	<input type="radio"/> Construction	<input type="radio"/> Tourism & Travel Services
<input type="radio"/> Electric Utilities	<input type="radio"/> REITS & Finance	<input type="radio"/> Other Travel
<input type="radio"/> Energy Conservation	<input type="radio"/> Residential	<input type="radio"/> Other
<input type="radio"/> Environmental Services	<input type="radio"/> Other Real Estate	
<input type="radio"/> Oil & Gas		
<input type="radio"/> Other Energy		

5. Issuer Size

Revenue Range

- ☐ No Revenues
- ☐ \$1 - \$1,000,000
- ☐ \$1,000,001 - \$5,000,000
- ☐ \$5,000,001 - \$25,000,000
- ☐ \$25,000,001 - \$100,000,000
- ☐ Over \$100,000,000
- ☒ Decline to Disclose
- ☐ Not Applicable

Aggregate Net Asset Value Range

- ☐ No Aggregate Net Asset Value
- ☐ \$1 - \$5,000,000
- ☐ \$5,000,001 - \$25,000,000
- ☐ \$25,000,001 - \$50,000,000
- ☐ \$50,000,001 - \$100,000,000
- ☐ Over \$100,000,000
- ☐ Decline to Disclose
- ☐ Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

<input type="checkbox"/>	Rule 504(b)(1) (not (i), (ii) or (iii))	<input type="checkbox"/>	Rule 505
<input type="checkbox"/>	Rule 504 (b)(1)(i)	<input checked="" type="checkbox"/>	Rule 506(b)
<input type="checkbox"/>	Rule 504 (b)(1)(ii)	<input type="checkbox"/>	Rule 506(c)
<input type="checkbox"/>	Rule 504 (b)(1)(iii)	<input type="checkbox"/>	Securities Act Section 4(a)(5)
<input type="checkbox"/>		<input type="checkbox"/>	Investment Company Act Section 3(c)

7. Type of Filing

☒ New Notice Date of First Sale ☐ First Sale Yet to Occur

☐ Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? ☐ Yes ☒ No

9. Type(s) of Securities Offered (select all that apply)

☐ Pooled Investment Fund Interests ☒ Equity

- ☐ Tenant-in-Common Securities ☐ Debt
- ☐ Mineral Property Securities ☒ Option, Warrant or Other Right to Acquire Another Security
- Security to be Acquired Upon
- ☒ Exercise of Option, Warrant or Other Right to Acquire Security ☒ Other (describe)

Each unit consists of one common share and one common share purchase warrant exercisable at any time prior to May 9, 2023 at an exercise price of CDN\$1.31 per common share.

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? ☐ Yes ☒ No

Clarification of Response (if Necessary)

11. Minimum Investment

Minimum investment accepted from any outside investor \$ USD

12. Sales Compensation

Recipient Recipient CRD Number ☐ None

Mackie Research USA Inc.

39670

(Associated) Broker or Dealer ☐ None

(Associated) Broker or Dealer CRD Number ☒ None

Mackie Research Capital Corporation

Street Address 1

Street Address 2

199 Bay Street, Suite 4500

Commerce Court West, Box 368

City

State/Province/Country

ZIP/Postal Code

Toronto

ONTARIO, CANADA

M5L 1G2

State(s) of Solicitation

☐ All States

☐ Foreign/Non-US

NEW YORK

13. Offering and Sales Amounts

Total Offering Amount \$ USD ☐ Indefinite

Total Amount Sold \$ USD

Total Remaining to be Sold \$ USD ☐ Indefinite

Clarification of Response (if Necessary)

The additional U.S.\$464,909.38 may be received upon the exercise of warrants sold in the U.S. The U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on May 9, 2018, which was CDN\$1.00=U.S.\$1.2856.

14. Investors

Select if securities in the offering have been or may be sold to persons who

☐ do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

1

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$ 26084 USD ☐ Estimate

Finders' Fees \$ 0 USD ☐ Estimate

Clarification of Response (if Necessary)

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0 USD ☐ Estimate

Clarification of Response (if Necessary)

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Acasti Pharma Inc.	/s/ Linda P. O'Keefe	Linda P. O'Keefe	Chief Financial Officer	2018-05-24

